The National Comprehensive Cancer Network Oncology Research Program has funded two investigators from NCCN member institutions through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib in the treatment of epidermal growth factor receptor-positive non-small cell lung cancer.
Saint Luke's Cancer Institute announced an affiliation with Washington University School of Medicine in St. Louis effective June 1, 2017, giving Saint Luke's cancer patients expanded access to clinical trials beginning in late summer.
The FDA Oncologic Drugs Advisory Committee May 24 voted 12-4 to recommend approval of neratinib for the extended adjuvant treatment of adult patients with early-stage ERBB2-positive breast cancer who have received prior adjuvant trastuzumab-based therapy.
H. Jean Khoury, an expert in hematologic malignancies at Winship Cancer Institute of Emory University, died May 22, after a year spent battling cancer. He was 50.
Photo by Gage SkidmoreThe White House has proposed cutting $7.2 billion from the NIH budget, with $1.2 billion coming out of NCI—a proposal that, if supported by Congress, would eviscerate the cancer research enterprise in the United States, critics say.
When Amy Reed enrolled at the University of Pennsylvania medical school in 2001, she could not have possibly imagined that she would save more lives as a patient than as a physician.
It's possible that there were pianos that Bob Comis didn't like.
Oncora Medical, a precision radiation oncology software company, and MD Anderson Cancer Center announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology. During phase I, MD Anderson oncologists and information technology professionals will work with Oncora’s team of data scientists and engineers to install Oncora’s Precision Radiation […]
Novartis said the European Commission has approved Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer.
Janssen Research & Development, LLC said FDA has accepted for review a supplemental New Drug Application for ibrutinib (Imbruvica) for the treatment of patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.
